

## **APPENDIX VI**

## **STATUTORY AND GENERAL INFORMATION**

### **A. FURTHER INFORMATION ABOUT OUR GROUP**

#### **1. Establishment of Our Company**

Our Company was established as a limited liability company in the PRC on October 28, 2015 and was converted to a joint stock company with limited liability under the laws of the PRC with effect from March 10, 2022. As of the Latest Practicable Date, the registered capital of our Company was RMB360,000,000 divided into 360,000,000 Unlisted Shares with a nominal value of RMB1.00 each.

Our Company has established a principal place of business in Hong Kong at 40th Floor, Dah Sing Financial Centre, 248 Queen’s Road East, Wanchai, Hong Kong and has been registered with the Registrar of Companies in Hong Kong as a non-Hong Kong company in Hong Kong under Part 16 of the Companies Ordinance on January 13, 2025. Ms. Lin Sio Ngo, one of our joint company secretaries, has been appointed as the authorized representative of our Company for the acceptance of service of process and notices on behalf of our Company in Hong Kong.

As our Company was established in the PRC, our corporate structure and Articles of Association are subject to the relevant laws and regulations of the PRC. A summary of the relevant provisions of our Articles of Association is set out in “Appendix V—Summary of Articles of Association” to this document.

#### **2. Changes in the Share Capital of Our Company**

As of the date of the establishment of our Company, our registered capital was RMB10,000,000. On March 10, 2022, our Company was converted into a joint stock company with limited liability under the laws of the PRC. Upon completion of such conversion, the registered capital of our Company was RMB360,000,000 divided into 360,000,000 Unlisted Shares with a nominal value of RMB1.00 each. There has been no alteration in our share capital within the two years immediately preceding the date of this document.

#### **3. Changes in the Share Capital of Our Subsidiary**

Details of our subsidiary is set out in “History, Development and Corporate Structure—Our Subsidiary” and Note 41 to the Accountants’ Report as set out in Appendix I to this document. There has been no alteration in the share capital of the subsidiary of our Company within two years immediately preceding the date of this document.

#### **4. Restriction of Share Repurchase**

For details of the restrictions on the share repurchase by our Company, see “Appendix V—Summary of Articles of Association” to this document.

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

### 5. Resolutions of Our Shareholders

At the extraordinary general meeting of our Company held on January 8, 2025, among other things, our Shareholders had resolved that:

- (a) the issue of H Shares with a nominal value of RMB1.00 each shall be approved and such H Shares shall be listed on the Stock Exchange;
- (b) the number of H Shares to be issued shall be no more than 25% of the total issued share capital of our Company as enlarged by the [REDACTED] before the exercise of the [REDACTED];
- (c) subject to the filing with CSRC is completed, the Conversion of Unlisted Shares into H Shares upon completion of the [REDACTED] shall be approved;
- (d) subject to the completion of the [REDACTED], the conditional adoption of the Articles of Association, which shall become effective on the Listing Date; and
- (e) our Board and/or its authorized person(s) have been authorized to handle all relevant matters relating to, among other things, the [REDACTED], Conversion of Unlisted Shares into H Shares, the issue of H Shares and the Listing.

### B. FURTHER INFORMATION ABOUT OUR BUSINESS

#### 1. Summary of Material Contracts

We have entered into the following contracts (not being contracts entered into in the ordinary course of business) within the two years preceding the date of this document that are or may be material:

- (a) the termination agreement of the shareholders’ special rights dated May 23, 2023 entered into among Jiangsu Jiequan Gaotejia Medical Industry Investment Fund (Limited Partnership) (江蘇捷泉高特佳醫療產業投資基金(有限合夥)), Qingdao Yingke Value Venture Capital Partnership (Limited Partnership) (青島盈科價值創業投資合夥企業(有限合夥)), HLC Healthmedical HK Limited, Taizhou Jintai Hongyi Entrepreneurship Investment Fund (Limited Partnership) (泰州市金泰弘毅創業投資基金(有限合夥)), Zhuzhou National Innovation Medicine Investment Partnership (Limited Partnership) (株洲市國創新藥投資合夥企業(有限合夥)), Pingtan Wenzhou Hangshi Ruihui Investment Partnership (Limited Partnership) (平潭文周杭實瑞慧投資合夥企業(有限合夥)), Hangzhou Sanhua Hongdao Venture Capital Partnership Enterprise (Limited Partnership) (杭州三花弘道創業投資合夥企業(有限合夥)), Taizhou China Pharmaceutical City Class I New Drug R&D Investment Fund Partnership Enterprise (Limited Partnership) (泰州中國醫藥城一類新藥研發投資基金合夥企業(有限合夥)), Zhuzhou Sealand Guochuang Qianjin Pharmaceutical Venture Capital Partnership (Limited Partnership) (株洲市國海國創千金醫藥創業投資合夥企業(有限合夥)), Shenzhen Songhe JiYou No. 3 Venture Capital Partnership

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

(Limited Partnership) (深圳市松禾績優三號創業投資合夥企業(有限合夥)), Shenzhen Sealand No. 5 Innovative Pharmaceutical Investment Partnership (Limited Partnership) (深圳市國海伍號創新醫藥投資合夥企業(有限合夥)), Shenzhen Co-win Yuanshui Investment Partnership (Limited Partnership) (深圳共贏源水投資合夥企業(有限合夥)), Yangzhou Yingdan Equity Investment Partnership (Limited Partnership) (揚州盈丹股權投資合夥企業(有限合夥)), Anji Aiweidi Enterprise Management Partnership (Limited Partnership) (安吉愛威笛企業管理合夥企業(有限合夥)), Guangxi Sealand Yuchai Venture Capital Partnership (Limited Partnership) (廣西國海玉柴金投創業投資合夥企業(有限合夥)), Gongqingcheng Chengshu Phase V Medical Industry Investment Partnership (Limited Partnership) (共青城承樹五期醫療產業投資合夥企業(有限合夥)), Hangzhou Fushi Investment Management Partnership (Limited Partnership) (杭州賦實投資管理合夥企業(有限合夥)), Shenzhen Gaotejia Ruibao Investment Partnership (Limited Partnership) (深圳市高特佳睿寶投資合夥企業(有限合夥)), Taizhou Transition and Upgrading Industrial Investment Fund (Limited Partnership) (泰州市轉型升級產業投資基金(有限合夥)), Jiangsu Province Modern Service Industry Development Venture Capital Fund (Limited Partnership) (江蘇省現代服務業發展創業投資基金(有限合夥)), Shenzhen Dongqi Investment Development Enterprise (Limited Partnership) (深圳東淇投資發展企業(有限合夥)), Suzhou Yihui Entrepreneurship Investment Partnership Enterprise (Limited Partnership) (蘇州益慧創業投資合夥企業(有限合夥)), Zhuzhou Litian New Drug Enterprise Management Partnership (Limited Partnership) (株洲市利田新藥企業管理合夥企業(有限合夥)), Xinchang Yujun Shanghang Venture Capital Partnership (Limited Partnership) (新昌鈺俊尚行創業投資合夥企業(有限合夥)), Xi'an Sealand Jingheng Venture Capital Co., Ltd. (西安國海景恒創業投資有限公司), Shangshan Ruoshui (Beijing) Fund Management Co., Ltd. (上善若水(北京)基金管理有限公司), Qingdao Yingke Dingxin No. 1 Venture Capital Partnership (Limited Partnership) (青島盈科鼎新一號創業投資合夥企業(有限合夥)), Pingtan Wenzhou Ruixi Investment Partnership (Limited Partnership) (平潭文周瑞璽投資合夥企業(有限合夥)), Guangxi Guangtou Guohong Health Industry Fund Partnership Enterprise (Limited Partnership) (廣西廣投國宏健康產業基金合夥企業(有限合夥)), Pingtan Puxin Yingke Ruiyuan Venture Capital Partnership (Limited Partnership) (平潭浦信盈科睿遠創業投資合夥企業(有限合夥)), Zhuzhou Wenzhou Junzhe Venture Capital Partnership (Limited Partnership) (株洲市文周君喆創業投資合夥企業(有限合夥)), Yangzhou Xuantan Investment Co., Ltd. (揚州玄壇投資有限公司), Qingdao Qiandao Yingyue Investment Management Center (Limited Partnership) (青島乾道盈悅投資管理中心(有限合夥)), Nanjing Yidao Equity Investment Partnership (Limited Partnership) (南京益道股權投資合夥企業(有限合夥)), Zibo Yingke Growth No. 2 Venture Capital Partnership (Limited Partnership) (淄博盈科成長二號創業投資合夥企業(有限合夥)), Shenzhen Zhiyou Pengbo Management Consulting Partnership (Limited Partnership) (深圳市志友蓬勃管理諮詢合夥企業(有限合夥)), Mr. An Youcai (安有才), Jiangsu Tiaoyu Enterprise Management Consulting Co., Ltd. (江蘇耀宇企業管理諮詢有限公司), Mr. He Yiming (何一鳴), Taizhou Huida Enterprise Management Consulting Service Partnership (Limited Partnership) (泰州慧達企業管理諮詢服務合夥企業(有限合夥)), Taizhou Huirong Enterprise Management Consulting Service Partnership (Limited Partnership) (泰州慧融企業管理諮詢服務合夥企業(有限合夥)), Taizhou

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

Huilong Enterprise Management Consulting Service Partnership (Limited Partnership) (泰州慧隆企業管理諮詢服務合夥企業(有限合夥)), Shanghai Yijiucheng Investment Co., Ltd. (上海憶久誠投資有限公司) and the Company, pursuant to which the termination and reinstatement of shareholders' special rights were agreed among the aforementioned parties.

- (b) the supplemental agreement to the termination agreement of the shareholders' special rights dated [●] entered into among Jiangsu Jiequan Gaotejia Medical Industry Investment Fund (Limited Partnership) (江蘇捷泉高特佳醫療產業投資基金(有限合夥)), Qingdao Yingke Value Venture Capital Partnership (Limited Partnership) (青島盈科價值創業投資合夥企業(有限合夥)), HLC Healthmedical HK Limited, Taizhou Jintai Hongyi Entrepreneurship Investment Fund (Limited Partnership) (泰州市金泰弘毅創業投資基金(有限合夥)), Zhuzhou National Innovation Medicine Investment Partnership (Limited Partnership) (株洲市國創新藥投資合夥企業(有限合夥)), Pingtan Wenzhou Hangshi Ruihui Investment Partnership (Limited Partnership) (平潭文周杭實瑞慧投資合夥企業(有限合夥)), Hangzhou Sanhua Hongdao Venture Capital Partnership Enterprise (Limited Partnership) (杭州三花弘道創業投資合夥企業(有限合夥)), Taizhou China Pharmaceutical City Class I New Drug R&D Investment Fund Partnership Enterprise (Limited Partnership) (泰州中國醫藥城一類新藥研發投資基金合夥企業(有限合夥)), Zhuzhou Sealand Guochuang Qianjin Pharmaceutical Venture Capital Partnership (Limited Partnership) (株洲市國海國創千金醫藥創業投資合夥企業(有限合夥)), Shenzhen Songhe JiYou No. 3 Venture Capital Partnership (Limited Partnership) (深圳市松禾績優三號創業投資合夥企業(有限合夥)), Shenzhen Sealand No. 5 Innovative Pharmaceutical Investment Partnership (Limited Partnership) (深圳市國海伍號創新醫藥投資合夥企業(有限合夥)), Shenzhen Co-win Yuanshui Investment Partnership (Limited Partnership) (深圳共贏源水投資合夥企業(有限合夥)), Yangzhou Yingdan Equity Investment Partnership (Limited Partnership) (揚州盈丹股權投資合夥企業(有限合夥)), Anji Aiweidi Enterprise Management Partnership (Limited Partnership) (安吉愛威笛企業管理合夥企業(有限合夥)), Guangxi Sealand Yuchai Venture Capital Partnership (Limited Partnership) (廣西國海玉柴金投創業投資合夥企業(有限合夥)), Gongqingcheng Chengshu Phase V Medical Industry Investment Partnership (Limited Partnership) (共青城承樹五期醫療產業投資合夥企業(有限合夥)), Hangzhou Fushi Investment Management Partnership (Limited Partnership) (杭州賦實投資管理合夥企業(有限合夥)), Shenzhen Gaotejia Ruibao Investment Partnership (Limited Partnership) (深圳市高特佳睿寶投資合夥企業(有限合夥)), Taizhou Transition and Upgrading Industrial Investment Fund (Limited Partnership) (泰州市轉型升級產業投資基金(有限合夥)), Jiangsu Province Modern Service Industry Development Venture Capital Fund (Limited Partnership) (江蘇省現代服務業發展創業投資基金(有限合夥)), Shenzhen Dongqi Investment Development Enterprise (Limited Partnership) (深圳東淇投資發展企業(有限合夥)), Nanjing Yihui Entrepreneurship Investment Partnership Enterprise (Limited Partnership) (南京益慧創業投資合夥企業(有限合夥)), Yangzhou Litian New Drug Investment Partnership Enterprise (Limited Partnership) (揚州利田新藥投資合夥企業(有限合夥)), Xinchang Yujun Shanghang Venture Capital Partnership (Limited Partnership) (新昌鈺俊尚行創業投資合夥企業

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

(有限合夥)), Xi'an Sealand Jingheng Venture Capital Co., Ltd. (西安國海景恒創業投資有限公司), Shangshan Ruoshui (Beijing) Fund Management Co., Ltd. (上善若水(北京)基金管理有限公司), Qingdao Yingke Dingxin No. 1 Venture Capital Partnership (Limited Partnership) (青島盈科鼎新一號創業投資合夥企業(有限合夥)), Pingtan Wenzhou Ruixi Investment Partnership (Limited Partnership) (平潭文周瑞璽投資合夥企業(有限合夥)), Guangxi Guangtou Guohong Health Industry Fund Partnership Enterprise (Limited Partnership) (廣西廣投國宏健康產業基金合夥企業(有限合夥)), Pingtan Puxin Yingke Ruiyuan Venture Capital Partnership (Limited Partnership) (平潭浦信盈科睿遠創業投資合夥企業(有限合夥)), Zhuzhou Wenzhou Junzhe Venture Capital Partnership (Limited Partnership) (株洲市文周君喆創業投資合夥企業(有限合夥)), Yangzhou Xuantan Investment Co., Ltd. (揚州玄壇投資有限公司), Qingdao Qiandao Yingyue Investment Management Center (Limited Partnership) (青島乾道盈悅投資管理中心(有限合夥)), Nanjing Yidao Equity Investment Partnership (Limited Partnership) (南京益道股權投資合夥企業(有限合夥)), Zibo Yingke Growth No. 2 Venture Capital Partnership (Limited Partnership) (淄博盈科成長二號創業投資合夥企業(有限合夥)), Shenzhen Zhiyou Pengbo Management Consulting Partnership (Limited Partnership) (深圳市志友蓬勃管理諮詢合夥企業(有限合夥)), Mr. An Youcai (安有才), Jiangsu Tiaoyu Science and Trade Co., Ltd. (江蘇耀宇科貿有限公司), Mr. He Yiming (何一鳴), Taizhou Huida Enterprise Management Consulting Service Partnership Enterprise (Limited Partnership) (泰州慧達企業管理諮詢服務合夥企業(有限合夥)), Taizhou Huirong Enterprise Management Consulting Service Partnership (Limited Partnership) (泰州慧融企業管理諮詢服務合夥企業(有限合夥)), Taizhou Huilong Enterprise Management Consulting Service Partnership (Limited Partnership) (泰州慧隆企業管理諮詢服務合夥企業(有限合夥)), Shanghai Yijiucheng Investment Co., Ltd. (上海憶久誠投資有限公司) and the Company, pursuant to which the termination and reinstatement of shareholders' special rights were agreed among the aforementioned parties; and

(c) the [REDACTED].

## 2. Intellectual Property Rights

### (a) Trademarks

As of the Latest Practicable Date, we had registered the following trademarks which we consider to be or may be material to our business:

No.	Trademark	Class	Registered Owner	Place of Registration	Registration Number	Date of Expiry
1.	慧尔康美 HRK-M	5	Our Company	PRC	74673315	2034/04/13
2.	慧尔康达 HRK-D	5	Our Company	PRC	74662757	2034/04/13



## APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Trademark	Class	Registered Owner	Place of Registration	Registration Number	Date of Expiry
3. . .	慧尔康怡 HRK-Y	5	Our Company	PRC	74653388	2034/04/13
4. . .		5	Our Company	PRC	70273132	2033/10/27
5. . .		5	Our Company	PRC	70231092	2033/12/13
6. . .		5	Our Company	PRC	66830396A	2033/05/06
7. . .	慧尔康怡	5	Our Company	PRC	66240533	2033/01/27
8. . .	慧尔康达	5	Our Company	PRC	66223204	2033/01/20
9. . .	慧尔康美	5	Our Company	PRC	66226238	2033/01/20
10. . .	慧尔康泰 HRK-T	5	Our Company	PRC	31738627	2029/06/06
11. . .	慧尔康安 HRK-A	5	Our Company	PRC	31741688	2029/06/13
12. . .		5	Our Company	PRC	19988389	2027/09/06
13. . .	慧尔康欣 HRK-X	5	Our Company	PRC	19988186	2027/07/06
14. . .	慧儿康宁 HRK-N	5	Our Company	PRC	19988060	2028/05/06
15. . .	慧尔康泽 HRK-Z	5	Our Company	PRC	77288678	2034/09/06
16. . .	慧尔康泽 HRK-Z	35	Our Company	PRC	77268621	2034/08/27
17. . .		42	Our Company	PRC	70231367	2034/04/06
18. . .		05, 42	Yither Biotech	PRC	59999769	2032/04/13
19. . .	慧儿康宁	05	Our Company	PRC	78670821	2034/11/19

## APPENDIX VI STATUTORY AND GENERAL INFORMATION

As of the Latest Practicable Date, we had applied for the following trademarks which we consider to be or may be material to our business:

No.	Trademark	Class	Applicant	Place of Application	Application Number	Date of Application
1. . .	慧尔康欣 HRK-X	35	Our Company	PRC	81563127	2024/10/24
2. . .	 慧尔康宁	35	Our Company	PRC	81372536	2024/10/14
3. . .	 慧尔康宁	05	Our Company	PRC	81361001	2024/10/14
4. . .	中慧元通	35	Our Company	PRC	72842499	2023/07/14
5. . .	慧尔康欣 HRK-X	05, 35, 42	Our Company	Hong Kong	306707485	2024/10/29
6. . .	 中慧生物 Ab&B Bio-Tech	05, 35, 42	Our Company	Hong Kong	306707494	2024/10/29
7. . .	 中慧生物 Ab&B Bio-Tech	05, 35, 42	Our Company	Hong Kong	306707494	2024/10/29
8. . .	YH <sub>A</sub> APA	05	Our Company	PRC	83137312	2025/01/15
9. . .	YH <sub>A</sub> MAA	05	Our Company	PRC	83119646	2025/01/15
10. . .	YH <sub>A</sub> NAA	05	Our Company	PRC	83137318	2025/01/15
11. . .	YH <sub>AS</sub> SEA	05	Our Company	PRC	83122838	2025/01/15
12. . .	YH <sub>AS</sub> TEA	05	Our Company	PRC	83138793	2025/01/15
13. . .	YH <sub>AS</sub> EEA	05	Our Company	PRC	83128118	2025/01/15
14. . .	YH <sub>AS</sub> LPA	05	Our Company	PRC	83134279	2025/01/15

## APPENDIX VI STATUTORY AND GENERAL INFORMATION

### (b) Patents

As of the Latest Practicable Date, we had registered the following patents which we consider to be or may be material to our business:

No.	Patent	Type	Registered Owner	Place of Registration	Patent Number	Date of Application	Date of Expiry
1..	A refrigerated transport device for genetic engineering vaccines (一種基因工程疫苗用冷藏轉運裝置)	Invention	Our Company	PRC	202010912803.X	2020/09/02	2040/09/01
2..	A water bath device for cervical cancer vaccine production inspection (一種用於宮頸癌疫苗生產檢驗的水浴裝置)	Invention	Our Company	PRC	202010906705.5	2020/09/02	2040/09/01
3..	A storage device for prophylactic subunit influenza vaccine (一種預防用亞單位流感疫苗存放裝置)	Invention	Our Company	PRC	202010901382.0	2020/09/01	2040/08/31
4..	A high-efficiency inactivation device for vaccines (一種疫苗高效滅活裝置)	Invention	Our Company	PRC	202011191020.3	2020/10/30	2040/10/29
5..	A sterilization cabinet for vaccine production (一種疫苗生產用消毒櫃)	Invention	Our Company	PRC	202011345298.1	2020/11/26	2040/11/25
6..	A cold storage detection device for vaccines and its usage method (一種疫苗冷藏儲存檢測裝置及使用方法)	Invention	Our Company	PRC	202011404262.6	2020/12/03	2040/12/02
7..	A culture and isolation device for new coronavirus pneumonia vaccine R&D (一種新型冠狀病毒肺炎疫苗研發用培養及分離的裝置)	Invention	Our Company	PRC	202011388069.8	2020/12/01	2040/11/30



## APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Patent	Type	Registered Owner	Place of Registration	Patent Number	Date of Application	Date of Expiry
8..	A cultivation device for rabies vaccine research and development (一種用於狂犬疫苗研發的培養裝置)	Invention	Our Company	PRC	202011404241.4	2020/12/03	2040/12/02
9..	Centrifuge equipment for new coronavirus pneumonia vaccine reagent tubes (一種新型冠狀病毒肺炎疫苗試劑管離心設備)	Invention	Our Company	PRC	202011388070.0	2020/12/01	2040/11/30
10.	A test kit for detecting streptococcus pneumoniae 10A serotype (一種檢測肺炎球菌10A血清型的試劑盒)	Invention	Our Company	PRC	201710655873.X	2017/08/03	2037/08/02
11.	A safe workbench for quadrivalent influenza virus subunit vaccine R&D (一種四價流感病毒亞單位疫苗研發用安全實驗台)	Invention	Our Company	PRC	202210517954.4	2022/05/12	2042/05/11
12.	A negative pressure exhaust gas sterilization system for influenza vaccine R&D (一種流感病毒疫苗研發用負壓廢氣排放滅菌系統)	Invention	Our Company	PRC	202210303948.9	2022/03/25	2042/03/24
13.	A stirring device for rabies vaccine processing (一種狂犬疫苗加工用攪拌裝置)	Invention	Our Company	PRC	202211034799.7	2022/08/26	2042/08/25
14.	A heating and separation device for rabies vaccine production (一種狂犬疫苗生產用加熱分離裝置)	Invention	Our Company	PRC	202211112152.1	2022/09/13	2042/09/12

## APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Patent	Type	Registered Owner	Place of Registration	Patent Number	Date of Application	Date of Expiry
15.	A solid-liquid separation device for cervical cancer vaccine production (一種宮頸癌疫苗生產加工用固液分離裝置)	Invention	Our Company	PRC	202210925592.2	2022/08/03	2042/08/02
16.	A demulsification separation system for quadrivalent influenza vaccine processing (一種用於四價流感病毒亞單位疫苗加工用破乳分離系統)	Invention	Our Company	PRC	202210303949.3	2022/03/25	2042/03/24
17.	A high-efficiency mixing device for cervical cancer vaccine preparation (一種宮頸癌疫苗製備用的高效混合裝置)	Invention	Our Company	PRC	202211025676.7	2022/08/25	2042/08/24
18.	A demulsification and separation device for vaccine production (一種疫苗生產用破乳及分離裝置)	Invention	Our Company	PRC	202211463153.0	2022/11/16	2042/11/15
19.	A development system for universal influenza vaccine based on ferritin (一種基於鐵蛋白的通用流感疫苗用研發系統)	Invention	Our Company	PRC	202210321531.5	2022/03/25	2042/03/24
20.	A shockproof transport box for quadrivalent influenza virus subunit vaccine (一種四價流感病毒亞單位疫苗用的防震動轉運箱)	Invention	Our Company	PRC	202210453638.5	2022/04/24	2042/04/23
21.	A feed tube mechanism for a butterfly centrifuge (一種蝶式離心機的進料管機構)	Invention	Our Company	PRC	202310218733.1	2023/03/09	2043/03/08

## APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Patent	Type	Registered Owner	Place of Registration	Patent Number	Date of Application	Date of Expiry
22.	A stable chromatography purification device (一種柱層析穩定提純裝置)	Invention	Our Company	PRC	202310262424.4	2023/03/17	2043/03/16
23.	A sample injection device for chromatography systems (一種層析系統用進樣裝置)	Invention	Our Company, Yither Biotech	PRC	202310382327.9	2023/04/12	2043/04/11
24.	A fully automated embryonated egg inoculation machine (一種胚蛋全自動接種機)	Invention	Our Company, Yither Biotech	PRC	202310322102.4	2023/03/29	2043/03/28
25.	A concentration and purification device for influenza vaccine production (一種流感疫苗生產用濃縮純化裝置)	Invention	Our Company, Yither Biotech	PRC	202310426763.1	2023/04/20	2043/04/19
26.	A pipe clamp for vaccine ultra-filtration systems (一種疫苗超濾系統管道夾具)	Invention	Our Company	PRC	202310292859.3	2023/03/24	2043/03/23
27.	A sterilization device for inoculation machine needles (一種接種機針頭用的消毒裝置)	Invention	Our Company, Yither Biotech	PRC	202310623540.4	2023/05/30	2043/05/29
28.	A shaking mixing system for quadrivalent influenza virus subunit vaccine preparation (一種四價流感病毒亞單位疫苗製備搖動混合系統)	Invention	Our Company	PRC	202210714823.5	2022/06/23	2042/06/22
29.	A vaccine production ultracentrifuge with autonomous collection function (一種具有自主收集功能的疫苗生產超速離心機)	Invention	Our Company, Yither Biotech	PRC	202310605982.6	2023/05/26	2043/05/25

## APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Patent	Type	Registered Owner	Place of Registration	Patent Number	Date of Application	Date of Expiry
30.	A purification device for genetic engineering vaccine research (一種基因工程疫苗研發用的提純裝置)	Invention	Our Company	PRC	202211309672.1	2022/10/25	2042/10/24
31.	A rabies vaccine virus screening method based on in vivo and in vitro cross, and its application (一種基於體內外交叉的狂犬病疫苗病毒篩選方法、及應用)	Invention	Our Company	PRC	202211083453.6	2022/09/06	2042/09/05
32.	Poxvirus mRNA vaccine and its uses (痘病毒mRNA疫苗及用途)	Invention	Our Company, Yither Biotech	PRC	202310244097.X	2023/03/13	2043/03/12
33.	A truncated varicella-zoster virus gE protein and its application (一種截短型水痘-帶狀疱疹病毒gE蛋白及其應用)	Invention	Our Company, Yither Biotech	PRC	202310181926.4	2023/02/28	2043/02/27
34.	A method for preparing lipid nanoparticles carrying stable RNA molecules for nasal spray use (一種可鼻噴的穩定遞載RNA分子的脂質納米顆粒製備方法)	Invention	Yither Biotech	PRC	202110355364.1	2021/04/01	2041/03/31

As of the Latest Practicable Date, we had applied for the following patents which we consider to be or may be material to our business:

No.	Patent	Type	Applicant	Place of Application	Application Number	Date of Application
1.	A truncated varicella-zoster virus gE protein and its application (一種截短型水痘-帶狀疱疹病毒gE蛋白及其應用)	Invention	Our Company, Yither Biotech	International	PCT/CN2023/131489	2023/11/14

## APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Patent	Type	Applicant	Place of Application	Application Number	Date of Application
2. . .	Poxvirus mRNA vaccines and its usage (痘病毒 mRNA疫苗及用途)	Invention	Our Company, Yither Biotech	International	PCT/CN2024/080492	2024/03/07
3. . .	A sterile culture device for influenza vaccine preparation (一種流感疫苗制備用無菌培養裝置)	Invention	Our Company	PRC	202211338331.7	2022/10/28
4. . .	A nano-emulsion adjuvant (一種納米乳佐劑)	Invention	Our Company, Yither Biotech	PRC	202310388310.4	2023/04/12
5. . .	Protease B-deficient Hansenula yeast strain for expressing HPV 16 L1 protein and its application (用於表達HPV 16 L1蛋白的蛋白酶B缺失型漢遜酵母菌株及其應用)	Invention	Our Company, Yither Biotech	PRC	202311823309.6	2023/12/27
6. . .	Protease A-deficient Hansenula yeast strain for expressing HPV 16 L1 protein and its application (用於表達HPV 16 L1蛋白的蛋白酶A缺失型漢遜酵母菌株及其應用)	Invention	Our Company, Yither Biotech	PRC	202410301322.3	2024/03/15
7. . .	Protease double-deficient Hansenula yeast for expressing HPV 16 L1 protein (用於表達HPV 16 L1蛋白的蛋白酶雙缺失型漢遜酵母菌)	Invention	Our Company, Yither Biotech	PRC	202410691767.7	2024/05/30
8. . .	A lyophilized rabies vaccine for human and its preparation method (一種凍幹人用狂犬病疫苗及其制備方法)	Invention	Our Company	PRC	202411919292.9	2024/12/25
9. . .	Detection method for Span 85 content (司盤85含量的檢測方法)	Invention	Our Company, Yither Biotech	PRC	202411094254.4	2024/08/09
10. . .	Detection method for Triton N-101 content (裂解劑 Triton N-101含量的檢測方法)	Invention	Our Company, Yither Biotech	PRC	202411287387.3	2024/09/13

## APPENDIX VI STATUTORY AND GENERAL INFORMATION

No.	Patent	Type	Applicant	Place of Application	Application Number	Date of Application
11 . .	Preparation method for cryoprotectant and freeze-dried nucleic acid-lipid nanoformulation (冷凍保護劑和凍乾核酸-脂質納米製劑的製備方法)	Invention	Our Company, Yither Biotech	PRC	202411335992.3	2024/09/24
12 . .	An aluminum phosphate adjuvant and its preparation method (一種磷酸鋁佐劑及其製備方法)	Invention	Our Company, Yither Biotech	PRC	202411593791.3	2024/11/08
13 . .	Detection method for inactivator C11-15 secondary alcohol ethoxylate content (滅活劑C11-15仲醇聚氧乙烯醚含量的檢測方法)	Invention	Our Company, Yither Biotech	PRC	202411637214.X	2024/11/15
14 . .	Recombinant respiratory syncytial virus vaccine and its preparation method (重組呼吸道合胞病毒疫苗及其製備方法)	Invention	Our Company, Yither Biotech	PRC	202411637212.0	2024/11/15

### (c) Copyrights

As of the Latest Practicable Date, we had registered the following copyrights which we consider to be or may be material to our business:

No.	Copyright	Registered Owner	Type	Copyright Number	Date of Registration
1 . . .	Zhonghui Yuantong (中慧元通)	Our Company	Artistic work	國作登字-2023-F-00080432	2023/05/05
2 . . .	Zhonghui Shengwu (中慧生物)	Our Company	Artistic work	國作登字-2023-F-00080433	2023/05/05
3 . . .	Zhonghui (中慧)	Our Company	Artistic work	國作登字-2023-F-00080434	2023/05/05
4 . . .	Huier (慧爾)	Our Company	Artistic work	蘇作登字-2023-F-00068474	2023/03/28



## APPENDIX VI STATUTORY AND GENERAL INFORMATION

### (d) *Domain names*

As of the Latest Practicable Date, our Group had registered the following domain names which we consider to be or may be material to our business:

No.	Domain name	Registered Owner	Date of Registration	Date of Expiry
1. . . . .	abbbio.com.cn	Our Company	2019/04/08	2025/04/08
2. . . . .	abbbio.cn	Our Company	2019/08/02	2025/08/02
3. . . . .	abbbio.com	Our Company	2015/10/13	2028/10/13
4. . . . .	yitherbiotech.com	Yither Biotech	2021/02/02	2026/02/02

## C. FURTHER INFORMATION ABOUT DIRECTORS, SUPERVISORS AND SUBSTANTIAL SHAREHOLDERS

### 1. Disclosure of Interests

#### (a) *Directors, Supervisors and the chief executive of our Company*

Save as disclosed in the section headed “Substantial Shareholders” in this document, immediately following the completion of the [REDACTED] and conversion of Unlisted Shares into H Shares, so far as our Directors are aware, none of our Directors, Supervisors or chief executive of our Company as any interests or short positions in the Shares, underlying Shares and debentures of our Company or its associated corporations (within the meaning of Part XV of the SFO) which will be required to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO) or which will be required, under section 352 of the SFO, to be entered in the register referred to in that section, or which will be required, under the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix 10 to the Listing Rules (the “**Model Code**”), to be notified to our Company and the Stock Exchange once the H Shares are listed.

#### (b) *Substantial Shareholders*

For the information on the persons who will, immediately following the completion of the [REDACTED], have interests or short positions in our Shares or underlying Shares which would be required to be disclosed to our Company and the Hong Kong Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or directly or indirectly be interested in 10% or more of the nominal value of any class of share capital carrying voting rights in all circumstances at general meetings of our Company, see “Substantial Shareholders” in this document.

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

Save as disclosed in the section headed “Substantial Shareholders” in this document, our Directors are not aware of any persons (other than our Directors, Supervisors and chief executive) who will, immediately following the completion of the [REDACTED], have or be deemed or taken to have interests and/or short position in our Shares or underlying Shares which would be required to be disclosed under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who is, directly or indirectly, interested in 10% or more of the nominal value of any types of the issued voting shares of any member of our Group.

### 2. Service Contracts

Pursuant to Rules 19A.54 and 19A.55 of the Listing Rules, we [have entered] into a contract with each of our Directors and Supervisors in respect of, among other things, compliance with the relevant laws and regulations, the Articles of Association and applicable provisions on arbitration.

Each of our Directors [has entered] into a service contract with our Company. The principal particulars of these service contracts comprise (a) a term of three years which is equivalent to the term of the Board; and (b) termination provisions in accordance with their respective terms. Our Directors may be re-appointed subject to Shareholders’ approval. The service contracts can be renewed pursuant to our Articles of Association and applicable rules.

Each of our Supervisors [has entered] into a contract with our Company. Each contract contains provisions relating to compliance with relevant laws and regulations, observation of our Articles of Association and resolution of disputes by means of arbitration.

Save as disclosed above, we have not entered, and do not propose to enter, into any service contracts with any of our Directors or Supervisors in their respective capacities as Directors or Supervisors (other than contracts expiring or determinable by the employer within one year without any payment of compensation (other than statutory compensation)).

### 3. Directors’ and Supervisors’ Remuneration

Save as disclosed in “Directors, Supervisors and Senior Management” and Note 13 to “Appendix I—Accountants’ Report” for the financial year ended December 31, 2023 and nine months ended September 30, 2024, none of our Directors or Supervisors received other remunerations or benefits in kind from us.

### 4. Disclaimers

Save as disclosed in this document:

- (a). none of our Directors, Supervisors or any of the parties listed in “—E. Other Information—4. Qualification and Consents of Experts” of this Appendix is:

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

- (i) interested in our promotion, or in any assets which, within the two years immediately preceding the date of this Document, have been acquired or disposed of by or leased to us, or are proposed to be acquired or disposed of by or leased to our Company; or
  - (ii) materially interested in any contract or arrangement subsisting at the date of this Document which is significant in relation to our business;
- (b). save in connection with the [REDACTED] and the [REDACTED], none of our Directors, Supervisors or any of the parties listed in “—E. Other Information—4. Qualification and Consents of Experts” of this Appendix:
  - (i) is interested legally or beneficially in any shares in any member of our Group; or
  - (ii) has any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for any securities in any member of our Group;
- (c). none of our Directors or Supervisors or their close associates or any shareholders of our Company who to the knowledge of our Directors owns more than 5% of our issued share capital has any interest in our top five customers or suppliers; and
- (d). none of our Directors or Supervisors is a director or employee of a company that has an interest in the share capital of our Company which, once the H Shares are listed on the Hong Kong Stock Exchange, would have to be disclosed pursuant to Divisions 2 and 3 of Part XV of the SFO.

### D. EMPLOYEE INCENTIVE SCHEMES

To fully incentivize our employees, maintain the stability of our management team and talents and attract high-quality talents, we established Taizhou Huirong, Taizhou Huilong, Taizhou Huida, Taizhou Huining, Taizhou Huixin and Taizhou Huijia as our Employee Ownership Platforms. See “History, Development and Corporate Structure—Employee Ownership Platforms” for further details.

The following is a summary of the principal terms of the 2017 Employee Incentive Scheme and the 2020 Employee Incentive Scheme (collectively, the “**Employee Incentive Schemes**”), respectively. Under the Employee Incentive Schemes, Eligible Participants (as defined below) were granted partnership interests in the Employee Ownership Platforms (“**Awards**”).

The Employee Incentive Schemes are not subject to the provisions of Chapter 17 of the Listing Rules as they do not involve any grant of share options or awards or any issuance of new Shares by our Company after Listing. Given the Shares under the Employee Incentive

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

Schemes have already been issued to the Employee Ownership Platforms as of the Latest Practicable Date, there will not be any dilutive effect to the issued Shares as a result of the operation of the Employee Incentive Schemes. The principal terms of the Employee Incentive Schemes are set out in the implementation rules of Equity Incentive Scheme of the Employee Ownership Platforms.

### (a) Purposes

The purposes of the Employee Incentive Schemes is to fully incentivize our employees, maintain the stability of our management team and talents and attract high-quality talents.

### (b) Eligible Participants

The eligible participants of our Employee Incentive Schemes are primarily the directors, management members and other key employees of our Group.

### (c) Administration

The Board or its designated personnel or institutions (the “**Administrator**”) are responsible for managing the Employee Ownership Platforms and interpreting the Employee Incentive Schemes, including but not limited to determining and adjusting the eligible participants of the Employee Incentive Schemes (the “**Participants**”), the date and quantity of grant and other specific matters such as whether to adopt lock-up restriction, the vesting period and the employment or service period.

### (d) Shares under the Employee Incentive Schemes

As of the Latest Practicable Date, the Employee Ownership Platforms held in aggregate 34,974,593 underlying Shares, representing approximately 9.72% of the issued share capital of our Company. Immediately upon completion of the [REDACTED] (assuming the [REDACTED] is not exercised), the Employee Ownership Platforms will be interested in approximately [REDACTED] of the total issued share capital of our Company.

Set out below is the holding structure of our Employee Ownership Platforms as of the Latest Practicable Date:

- **Taizhou Huirong:** As of the Latest Practicable Date, Taizhou Huirong had 25 limited partners who are current employees of the Group, among whom, Mr. He (our executive Director) held approximately 2.60% partnership interests as a limited partner therein. None of the limited partners of Taizhou Huirong holds more than one third of the partnership interests therein.
- **Taizhou Huilong:** As of the Latest Practicable Date, Taizhou Huilong had ten limited partners who are current employees of the Group, among whom, Mr. An, Mr. He (our executive Directors) and Mr. Feng Hao (封浩) (our Supervisor) held

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

approximately 20.40%, 4.00% and 2.80% partnership interests as limited partners therein, respectively. None of the limited partners of Taizhou Huilong holds more than one third of the partnership interests therein.

- **Taizhou Huida:** As of the Latest Practicable Date, Taizhou Huida had 48 limited partners, including Taizhou Huixin, Taizhou Huining and 46 current employees of the Group, among whom, (i) Mr. An, Mr. He (our executive Directors), Mr. Feng Hao and Mr. Wang Wei (王威) (our Supervisors) held approximately 2.17%, 0.87%, 0.52% and 0.35% partnership interests as limited partners therein, respectively; (ii) and each of Taizhou Huixin and Taizhou Huining held approximately 58.26% and 15.22% partnership interests as limited partners therein, respectively. Apart from Taizhou Huixin, none of the limited partners of Taizhou Huida holds more than one third of the partnership interests therein.
- **Taizhou Huining:** As of the Latest Practicable Date, Taizhou Huining had 44 limited partners who are current employees of the Group, among whom, Mr. An (our executive Director) held approximately 20.57% partnership interests as a limited partner therein. None of the limited partners of Taizhou Huining holds more than one third of the partnership interests therein.
- **Taizhou Huixin:** As of the Latest Practicable Date, Taizhou Huixin had 48 limited partners, including Taizhou Huijia and 47 current employees of the Group, among whom, (i) Mr. An, Ms. Li Runxiang (李潤香) and Mr. He, each of whom is an executive Director, approximately held 12.39%, 5.97% and 2.99% partnership interests as limited partners therein, respectively; (ii) Mr. Feng Hao, our Supervisor, held approximately 2.54% partnership interests as a limited partner therein, respectively; and (iii) Taizhou Huijia held approximately 14.93% partnership interest as a limited partner therein. None of the limited partners of Taizhou Huixin holds more than one third of the partnership interests therein.
- **Taizhou Huijia:** As of the Latest Practicable Date, Taizhou Huijia had 46 limited partners who are current employees of the Group, among whom, Mr. An (our executive Director) held approximately 25.00% partnership interests as a limited partner therein. None of the limited partners of Taizhou Huijia holds more than one third of the partnership interests therein.

All partnership interests in the Employee Ownership Platforms have been subscribed by and fully paid up by the Participants. No further Awards will be granted after the date of this Document and the Employee Incentive Schemes will not cause any dilution of the shareholding of our Shareholders after the Listing.

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

### (e) Lock-up restrictions

The partnership interests held by the Participants in the Employee Ownership Platforms, which represent the Awards granted to the Participants, are subject to lock-up restrictions for a period commencing from the date of signing respective employee incentive agreement to the date of completion of five years (for 2017 Employee Incentive Scheme, unless otherwise provided under the related award agreements as determined at the absolute discretion of the Company) or three years (for 2020 Employee Incentive Scheme) of service of the Participant with our Group. The Employee Incentive Schemes provide for certain circumstances in which the partnership interests granted to the Participants may be repurchased by and/or transferred to Jiangsu Tiaoyu as the general partner of the Employee Ownership Platforms or its designated persons or other limited partner(s) of the Employee Ownership Platforms during the lock-up period. Such circumstances include, without limitation, (i) termination of Participant's employment relationship with the Group; and (ii) death of the Participant, disability rendering the Participant unable to undertake his/her work assigned by the Group, or legal incapacity of the Participant.

After the [REDACTED], in addition to the restrictions under the Employee Incentive Schemes, the transfer or sale by the Participants shall be subject to the lock-up requirements under the relevant laws and regulations and the rules of the Stock Exchange, or the respective agreements entered into between the Company and the relevant Participants pursuant to the terms of the Employee Incentive Schemes (if applicable).

### E. OTHER INFORMATION

#### 1. Estate Duty

Our Directors have been advised that no material liability for estate duty is likely to impose on our Company or our subsidiary.

#### 2. Litigation

Saved as disclosed in this document, to the knowledge of our Directors, no member of our Group has significant litigation or claims pending or threatened against any member of our Group.

#### 3. Joint Sponsors

The Joint Sponsors satisfy the independence criteria applicable to sponsors as set out in Rule 3A.07 of the Listing Rules.

The Joint Sponsors have made an application on behalf of our Company to the Stock Exchange for the listing of, and permission to deal in, the H Shares to be converted from Unlisted Shares and the H Shares to be issued pursuant to the [REDACTED]. The Joint Sponsors will receive an aggregate fee of US\$600,000 for acting as the sponsors for the Listing.



## APPENDIX VI STATUTORY AND GENERAL INFORMATION

### 4. Qualification and Consents of Experts

The qualifications of the experts who have given opinions or advice in this document are as follows:

Name	Qualification
CITIC Securities (Hong Kong) Limited . . . . .	Licensed to conduct Type 4 (advising on securities) and Type 6 (advising on corporate finance) of regulated activities as defined under the SFO
CMB International Capital Limited . . . . .	Licensed to conduct Type 1 (dealing in securities) and Type 6 (advising on corporate finance) of regulated activities as defined under the SFO
Deloitte Touche Tohmatsu . . . . .	Certified Public Accountants under Professional Accountant Ordinance (Chapter 50 of the Laws of Hong Kong)  Registered Public Interest Entity Auditors under the Accounting and Financial Reporting Council Ordinance (Chapter 588 of the Laws of Hong Kong)
Grandway Law Offices . . . . .	Legal advisors to our Company as to the PRC law
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co. . . . .	Independent industry consultant

Each of the experts has given and has not withdrawn its written consents to the issue of this document with the inclusion of its reports, letters, opinions or summaries of opinions (as the case may be) and the references to its names and logos included herein in the form and context in which it is respectively included.

Save as disclosed in this document, as of the Latest Practicable Date, none of the experts named above has any of our shareholding interests in any member of our Group or rights (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for our securities in any member of our Group.

### 5. Compliance Advisor

Our Company has appointed Octal Capital Limited as its Compliance Advisor in compliance with Rule 3A.19 of the Listing Rules.

## **APPENDIX VI**

## **STATUTORY AND GENERAL INFORMATION**

### **6. Taxation of Holders of H Shares**

Hong Kong stamp duty, currently charged at the ad valorem rate of 0.10% on the higher of the consideration for or the market value of the H Shares, will be payable by the purchaser on every purchase and by the seller on every sale of any Hong Kong securities, including H Shares (in other words, a total of 0.20% is currently payable on a typical sale and purchase transaction involving H Shares). In addition, a fixed stamp duty of HK\$5.00 is currently payable on any instrument of transfer of H Shares. Where one of the parties is a resident outside Hong Kong and does not pay the ad valorem duty due by it, the duty not paid will be assessed on the instrument of transfer (if any) and will be payable by the transferee. If no stamp duty is paid on or before the due date, a penalty of up to ten times the duty payable may be imposed.

### **7. Binding Effect**

This document shall have the effect, if any application is made pursuant hereto, of rendering all persons concerned bound by all the provisions (other than the penal provisions) of sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance so far as applicable.

### **8. Bilingual Document**

The English language and Chinese language versions of this document are being published separately, in reliance upon the exemption provided by section 4 of the Companies (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).

### **9. Promoters**

The promoters of our Company comprised all of the 42 then Shareholders of our Company as of March 10, 2022 before our conversion into a joint stock company with limited liability. Save as disclosed in this document, within the two years immediately preceding the date of this document, no cash, securities or benefits have been paid, allotted or given, or are proposed to be paid, allotted or given to the promoters named above in connection with the [REDACTED] or the related transactions described in this document.

### **10. Preliminary Expenses**

Our Company did not incur any material preliminary expenses.

## APPENDIX VI

## STATUTORY AND GENERAL INFORMATION

### 11. No Material Adverse Change

Our Directors confirm that, as of the date of this document, there has been no material adverse change in our financial or trading position or prospects since September 30, 2024 (being the date to which the latest audited consolidated financial statements of our Group were prepared).

### 12. Miscellaneous

- (a) within the two years immediately preceding the date of this document:
  - (i) save as disclosed in "History, Development and Corporate Structure" in this document, no share or loan capital of our Company or our subsidiary had been issued or agreed to be issued or proposed to be fully or partly paid either for cash or for a consideration other than cash;
  - (ii) no share or loan capital of our Company or our subsidiary is under option or is agreed conditionally or unconditionally to be put under option;
  - (iii) save as disclosed in "[REDACTED]" in this document, no commissions, discounts, brokerages or other special terms have been granted or agreed to be granted in connection with the issue or sale of any share or loan capital of our Company or our subsidiary; and
  - (iv) save as disclosed in "[REDACTED]" in this document, no commission has been paid or is payable for subscription, agreeing to subscribe, procuring subscription or agreeing to procure subscription of any share in our Company or our subsidiary;
- (b) there are no founder, management or deferred shares nor any debentures in our Company or our subsidiary;
- (c) there has not been any interruption in the business of our Group which may have or has had a significant effect on the financial position of our Group in the 12 months preceding the date of this document;
- (d) no company within our Group is presently listed on any stock exchange or traded on any trading system;
- (e) all necessary arrangements have been made to enable our H Shares to be admitted into CCASS for clearing and settlement;

---

**APPENDIX VI****STATUTORY AND GENERAL INFORMATION**

---

- (f) our Company has no outstanding convertible debt securities or debentures;
- (g) there is no arrangement under which future dividends are waived or agreed to be waived, and there is no restriction affecting the remittance of profits or repatriation of capital by us into Hong Kong from outside Hong Kong; and
- (h) none of the equity and debt securities of our Company, if any, is listed or dealt with in any other stock exchange nor is any listing or permission to deal being or proposed to be sought.